-
[Editor's note: With the recent news that the U.S. Food and Drug Administration (FDA) has approved a new HIV test that obtains results within one minute, domestic HIV testing and prevention strategies have a new tool to employ. AIDS Alert asked Philip Bligh, president of bioLytical Laboratories in Vancouver, British Columbia and Chicago, IL, to answer questions in writing about his company's INSTI test. His responses are shown in this Q&A story]:
-
Opt-out HIV testing goals by the Centers for Disease Control and Prevention (CDC) of Atlanta, GA, would have greater success if states were to reduce legislative barriers, an expert says.
-
Close on the heels of the first positive findings reported in microbicides and vaccine research ventures, the iPrEx study has shown that a pre-exposure prophylaxis (PrEP) combination drug demonstrates 44% additional protection from HIV infection.
-
As institutions continue to weather the economic downturn, the toll on IRB offices is showing. The trends of previous years fewer raises, more job cuts, increasing workloads continued in 2010, according to responses to IRB Advisor's annual Salary Survey.
-
Recruiting patients for Phase I oncology studies which are unlikely to provide therapeutic benefit to participants and which carry the risk of significant side effects raises unique issues in informed consent.
-
As more sophisticated imaging technologies are used in research, investigators and IRBs must grapple with an unintended side effect an increase in incidental findings (IF), or new health data unrelated to the study that is revealed about participants.
-
Researchers might find it tempting to collect data for socio-behavioral studies from social websites like Facebook. Their appeal is having fairly easy access and viewing a broad range of behavioral information.
-
An IRB looking to recruit a good non-scientist to the board may have to look no further than its own institution's medical library.
-
-
IRBs dealing with international or high-risk research can find some guidance on how to handle all stakeholders in studies in the recently-revised Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP).